National Engineering Research Centre of Targeted Biologics

The National Engineering Research Center of Targeted Biologics is a prominent Chinese research and development entity primarily operated by Hansoh Pharmaceutical. Established to advance the national pharmaceutical industry, the center focuses on the discovery and clinical development of innovative targeted therapies, including small molecules and biologics. Its core expertise lies in oncology, metabolic diseases, and central nervous system disorders, with a significant emphasis on antibody-drug conjugates (ADCs) and next-generation kinase inhibitors. The center serves as a critical bridge between laboratory innovation and large-scale industrialization, contributing to the commercial success of several proprietary drugs in the Chinese market.